In the BioHarmony Drug Report Database
Pegaspargase
Oncaspar (pegaspargase) is an enzyme pharmaceutical. Pegaspargase was first approved as Oncaspar on 1994-02-01. It is used to treat b-cell chronic lymphocytic leukemia, blast crisis, non-hodgkin lymphoma, and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma.
Trade Name
|
Oncaspar |
|---|---|
Common Name
|
pegaspargase |
ChEMBL ID
|
CHEMBL2108546 |
Indication
|
b-cell chronic lymphocytic leukemia, blast crisis, non-hodgkin lymphoma, precursor cell lymphoblastic leukemia-lymphoma |
Drug Class
|
Enzymes; PEGylated compounds |
Image (chem structure or protein)
